Welcome to our dedicated page for Kineta news (Ticker: $KA), a resource for investors and traders seeking the latest updates and insights on Kineta stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kineta's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kineta's position in the market.
Rhea-AI Summary
Kineta, a clinical-stage biotechnology company focused on novel immunotherapies in oncology, announced the publication of preclinical data on KVA12123 in Frontiers in Immunology. KVA12123 shows strong single-agent anti-tumor activity while minimizing cytokine-related adverse events, recognizing a unique VISTA epitope and binding at neutral and acidic pH. Key results include high affinity binding to VISTA, specificity against VISTA with no cross-reactivity against other B7 family members, and the ability to reverse T cell suppression by myeloid-derived suppressor cells. KVA12123 is currently being evaluated in a Phase 1/2 VISTA-101 open-label clinical trial as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors (NCT05708950).
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.9%
Tags
-
Rhea-AI Summary
Kineta, a clinical-stage biotechnology company (Nasdaq: KA), will host a virtual KOL event to discuss new data from the VISTA-101 clinical trial of KVA12123 in patients with advanced solid tumors. The event will feature presentations from key opinion leaders in immuno-oncology, discussing the potential for VISTA blocking immunotherapy to reverse immunosuppression in the tumor microenvironment and drive anti-tumor activity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.81%
Tags
-
Rhea-AI Summary
Kineta, Inc. (Nasdaq: KA) to present preclinical data on KVA12123, a VISTA blocking immunotherapy, at the 5th Annual Macrophage-Directed Therapies Summit. The presentation will cover the ongoing VISTA-101 Phase 1/2 clinical trial evaluating KVA12123 as a monotherapy and in combination with pembrolizumab in patients with advanced solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.27%
Tags
Rhea-AI Summary
Kineta, Inc. announces positive data from its VISTA-101 clinical trial evaluating KVA12123, the company's VISTA blocking immunotherapy, in patients with advanced solid tumors. The drug demonstrated excellent safety and tolerability, with no dose limiting toxicities observed. It exhibited a greater than dose-proportional pharmacokinetic profile and achieved a greater than 90% VISTA receptor occupancy at the 30 mg dose. Biomarker results showed significant immune responses and anti-tumor effects. Additional data from the trial is expected in Q2 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.74%
Tags
-
Rhea-AI Summary
Kineta, Inc. reports positive safety data from its VISTA-101 clinical trial. They enrolled the first patient for KVA12123 in combination with pembrolizumab. The company expects cash runway into early 2025. Financial highlights show a decrease in cash position and zero revenues for Q3 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary
Kineta, Inc. presented new preclinical data on their anti-CD27 agonist monoclonal antibodies at the SITC 38th Annual Meeting. The antibodies demonstrated high binding affinity and specificity, driving strong T cell and NK cell activation. They also showed antitumor efficacy as a single agent and in combination with checkpoint inhibitors in solid and hematological tumor models.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Kineta, Inc. announces dosing of first patient in Part B of Phase 1/2 clinical trial for its VISTA blocking immunotherapy, KVA12123, in combination with Merck's KEYTRUDA®
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.93%
Tags
-
Rhea-AI Summary
Kineta, Inc. to present new clinical and preclinical data on immuno-oncology therapies at SITC Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
-
Rhea-AI Summary
Kineta, Inc. to present at Oxford Global Immuno US 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.41%
Tags
Rhea-AI Summary
Kineta, Inc. closes registered direct offering, raising approximately $3 million.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.45%
Tags
Kineta, Inc.
Nasdaq:KA
KA Rankings
KA Stock Data
5.13M
6.59M
29.25%
12.05%
0.56%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
MERCER ISLAND
About KA
proteostasis therapeutics is discovering and developing novel small molecule therapeutics designed to control the body’s protein homeostasis, or proteostasis network. the proteostasis network maintains the body’s natural balance of proteins to protect us from numerous diseases. these novel therapies, or proteostasis regulators, are designed to treat multiple genetic and degenerative disorders associated with deficiencies of the proteostasis network, such as alzheimer’s disease, emphysema, huntington’s disease, and type ii diabetes.